Cabaletta Bio Starts Pivotal Myositis CAR-T Trial, Aims for 2027 BLA with Automated Manufacturing
Cabaletta Bio has launched its pivotal Phase II/III trial in patients with refractory myositis, dosing the first cohort this month. The company’s newly implemented automated CAR-T manufacturing platform is designed to shorten production to under two weeks and scale capacity to support a biologics license application by 2027.
1. Trial Initiation and Design
Cabaletta Bio has initiated a pivotal Phase II/III study enrolling patients with refractory myositis to evaluate safety and efficacy of its lead CAR-T candidate. The trial will dose initial cohorts this month and expand to multiple sites across the U.S., targeting both clinical response and biomarker readouts.
2. Automated CAR-T Manufacturing Platform
The company unveiled an automated manufacturing system capable of producing individualized CAR-T doses in under two weeks, compared with traditional 4–6 week processes. This platform integrates closed-system cell processing and real-time quality controls to increase throughput and reduce variability.
3. BLA Timeline and Strategic Impact
Cabaletta aims to leverage its streamlined manufacturing to file a biologics license application by 2027, contingent on positive pivotal data. Executing this timeline could de‐risk the program ahead of larger industry competitors and materially enhance the company’s valuation.